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Abstract 
Objective: The purpose of the current study was to test theory-based predictions of mediators 
and moderators of treatment effects of a pilot randomised controlled trial which aimed to 
increase adherence to preventive medication in stroke survivors via addressing both 
automatic (i.e. habitual responses) and reflective (i.e. beliefs and value systems) aspects of 
medication-taking behaviour. 
Methods: Sixty-two stroke survivors were randomly allocated to either an Intervention or 
Control group. Intervention participants received a brief two-session intervention aimed at 
increasing adherence via a) helping patients establish better medication-taking routines using 
implementation intentions plans (automatic) and b) eliciting and modifying any mistaken 
patient beliefs regarding medication and/or stroke (reflective). The Control group received 
similar levels of non-medication-related contact. Primary outcome was adherence to anti-
hypertensive medicine measured objectively over 3 months using an electronic pill bottle. 
Secondary outcome measures included self-reported adherence (including forgetting) and 
beliefs about medication. 
Results: Intervention participants had 10% greater adherence on doses taken on schedule 
(intervention 97%; control 87%, 95% CI (0.2, 16.2), p = .048), as well as significantly greater 
increases in self-reported adherence and reductions in concerns about medication. Treatment 
effects were mediated by reductions in both forgetting and concerns about medication; and 
moderated by the presence of pre-existing medication-taking routines. 
Conclusions: Addressing both automatic and reflective aspects of behaviour via helping 
stroke survivors develop planned regular routines for medication-taking and addressing any 
concerns or misconceptions about their medication can improve adherence and thus 
potentially patient outcomes.    
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Introduction 
Stroke is the fourth highest cause of mortality in the United States, and has been estimated to 
account for around 1 in every 18 deaths, with total U.S. direct and indirect economic costs of 
over $34 billion per annum in 2008; it is also a leading cause of disability, including mobility 
and speech problems, which frequently result in dependency in everyday activities (Roger et 
al., 2012). People who have a stroke or transient ischaemic attack (TIA) have a 30-43% risk 
of recurrent stroke within 5 years (Warlow et al., 2008), and hence an increased risk of 
further disability and reduced quality of life. This risk can be substantially reduced by taking 
combined preventive medication over the long-term (e.g. a combination of cholesterol 
lowering drugs, blood thinning drugs and anti-hypertensive medication can provide an 
absolute risk reduction of 8.5% in the first year and 4.1% annually for subsequent years) 
(Sudlow, 2008).  
Adherence to medication in a timely manner is a primary determinant of treatment 
success. Despite this, it is estimated that in developed countries, only 50% of patients who 
suffer from chronic diseases adhere to treatment recommendations (WHO, 2003). In 
particular, adherence to preventive medication in stroke survivors is often poor (Bushnell, 
Zimmer, Pan, Olson, & Zhao, 2010), despite its evident success at reducing the risk of future 
strokes. Non-adherence to medication may be either non-intentional or intentional (Clifford, 
Barber, & Horne, 2008). Non-intentional non-adherence represents a patient’s failure to 
actively remember, or in some cases physically manage, to take their medicine as prescribed. 
This frequently depends on their ability to develop adequate habitual routines, and is 
associated with automatic behaviour, triggered by environmental cues. Intentional non-
adherence is associated with beliefs about illness and treatment, particularly the perceived 
effectiveness and necessity of medication versus concerns about possible harmful effects, and 
represents a reflective choice of how to behave (Strack & Deutsch, 2004). 
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Temporal self-regulation theory (Hall & Fong, 2007) can help explain why many patients 
with chronic conditions do not achieve optimal medication adherence, as it can account for 
both non-intentional and intentional non-adherence. This theory attempts to incorporate both 
automatic (based on past experience or environmental cues) and reflective (based on beliefs 
or value systems) behavioural processes, alongside consideration of the short-term cost 
versus long-term gain, in order to explain why individuals do not always behave in a manner 
which will support their long-term health goals. Taking medication can be associated with 
immediate costs (e.g. having to obtain medication, side-effects) which are offset against 
longer-term gains. Patients’ beliefs in the efficacy of their medication may impact on their 
assessment of longer term benefits, especially as many chronic conditions, such as high blood 
pressure, are not associated with immediate symptoms; for example, patients with 
hypertension may choose not to take medication as they do not feel ill, and therefore 
conclude they are ‘healthy’ (Anthony, Valinsky, Inbar, Gabriel, & Varda, 2012), or because 
they see the condition as temporary (Meyer, Leventhal, & Gutmann, 1985). Patients’ 
adherence may also be affected by their motivation to reduce the short-term costs of taking 
medication. For example, patients often seek to minimise their intake of medicines, in part to 
reduce the risk of negative consequences such as side-effects (Pound et al., 2005). Temporal 
self-regulation theory posits that whilst behaviour is primarily a function of the perceived 
likelihood of expected outcomes and the values attached to them, it is moderated by both 
behavioural pre-potency (reflecting past performance (i.e. automatic or habitual responses) or 
environmental cues to action) and self-regulatory capacity (i.e. an individual’s ability to 
regulate their own behaviour). Both of these may affect patients’ ability to develop and 
adhere to adequate medication-taking routines which will in turn impact on the regularity of 
their medication-taking.  
Both non-intentional and intentional aspects are likely to play a part in non-adherence to 
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medication in stroke survivors. Non-intentional non-adherence (e.g. forgetting) is likely in 
this group, as age is a major risk factor for stroke, and stroke often causes cognitive 
impairment (such as memory loss), and even mild cognitive impairment has been associated 
with poor medication adherence in elderly populations (Hayes, Larimer, Adami, & Kaye, 
2009). As well as its effect on a patient’s ability to develop habitual medication-taking 
routines, cognitive impairment may also impact on patient’s judgement about the benefits of 
taking their medication. Elderly stroke survivors are likely to have complex medication 
regimes, and so any negative beliefs they hold about treatment and its consequences may lead 
to higher intentional non-adherence in this group. A recent study on determinants of 
adherence in stroke survivors supported temporal self-regulation theory: it identified that 
patients’ immediate concerns about their medication (e.g. that they would become dependent, 
or suffer serious side effects), and a lesser belief in its potential benefits were both related to 
poorer adherence (O’Carroll et al., 2011).  Further, those patients who had developed 
automatic medication-taking routines were likely to have higher adherence overall 
(Chambers et al., 2011).  
Preventing stroke reoccurrence by increasing adherence to secondary preventative 
medication may improve quality of life for individuals and will help cut healthcare costs and 
so is an important focus for intervention. Whilst some behavioural change techniques address 
both reflective and automatic components of behaviour, many do not. A review of existing 
interventions aimed at increasing adherence concluded that current studies have had only 
limited success and that more research is needed on combined approaches involving multiple 
strategies, as these have been most effective (Haynes, Ackloo, Sahota, McDonald, & Yao, 
2008).  
The current intervention was designed to address both reflective and habitual aspects of 
adherence behaviour in a brief, personalised intervention in stroke survivors. Reflective 
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behaviour (represented by intentional non-adherence) was targeted by examining and 
modifying any mistaken beliefs that patients may have about their medication and/or stroke, 
using a model which has proved successful in improving patients’ views of their illness, and 
led to better rehabilitation after myocardial infarction (Petrie, Cameron, Ellis, Buick, & 
Weinman, 2002). Habitual behaviour (represented by non-intentional non-adherence) was 
addressed by the use of a simple If-then plan (Implementation Intentions) (Gollwitzer, 1999), 
to be used by each patient as an aid to developing automatic routines for medication-taking, 
thereby reducing cognitive load and hence forgetting. Implementation intentions formation 
may be viewed as a self-regulatory tool which has been shown to be effective at increasing 
adherence to health-behaviours in older adults over sustained periods of time and may be 
particularly helpful in stroke survivors as it does not seem to be affected by age-related 
cognitive decline (e.g. Liu & Park, 2004). However, forming deliberate intentions to perform 
a behaviour may be obstructed by the existence of previous habits or cues (Lally & Gardner, 
2011).  Habit strength has been shown to moderate the effect of Implementation Intentions on 
change of negative health behaviours, for example where Implementation Intentions were 
found to reduce smoking only for those with weak initial smoking habits (Webb & Sheeran, 
2009). Thus with regard to medication adherence, it may be harder to persuade patients with 
ingrained habits for medication-taking, even if ineffective, to form or adopt an 
Implementations Intentions plan, which aims to change their established routines. In addition 
patients already using effective environmental cues may not gain any additional benefit from 
the development of a formalised Implementations Intentions plan. 
Both Implementation Intentions and belief modification have been shown to be helpful in 
increasing adherence to medication in other health conditions (e.g. Alhalaqia, Nawafleh, 
Clark, & Gray, 2012; Brown, Sheeran, & Reuber, 2009), but, to our knowledge, have never 
been used in combination in stroke survivors. The aims of this study, as stated in the study 
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protocol article (O’Carroll, Dennis, Johnston, & Sudlow, 2010), were to test whether this 
brief intervention would improve both intentional and non-intentional adherence to 
medication and to examine whether increased adherence would be mediated by changes in 
the behaviours targeted for change (i.e. reduced forgetting and reduced medication concerns). 
An additional aim was to test for any moderating effect of previous habits (i.e. existing 
environmental cues) on adherence; the hypothesis is that the intervention would be more 
effective for those with weak pre-existing habits (i.e. environmental cues). 
Methods 
Full details of methods for this pilot randomised controlled trial are reported in the protocol 
article (O’Carroll et al., 2010) and the simple treatment effects article (O’Carroll, Chambers, 
Dennis, Sudlow, & Johnston, 2013), in compliance with CONSORT (CONsolidated 
Standards of Reporting Trials) guidelines (Moher et al., 2010).. In this article only methods 
which are pertinent to the mediator and moderator analyses are reported. 
Participants 
Participants were recruited from consecutive discharges at the stroke unit at the Western 
General Hospital in Edinburgh. Inclusion criteria were first stroke or TIA, discharged to 
home, and taking any preventive stroke medication. All participants were white Caucasian 
and all gave written informed consent to take part. Ethical approval was granted by Lothian 
NHS Board, South East Scotland Research Ethics Committee.  
Measures 
MEMS (Medication Event Monitoring System, MEMS® Aardex Ltd, Switzerland)  
The primary outcome measure was electronically recorded openings using MEMS pill 
bottles, used in both treatment arms for 3 months. Following Brown et al. (2009), three 
variables were calculated i.e. a) percentage of doses taken (versus prescribed), b) percentage 
of days on which the correct dose was taken and c) percentage of doses taking on schedule 
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i.e. within +/- 3 hours of the median time taken.  
The Medication Adherence Report Scale (MARS) (Horne, 2004)  
The self-report MARS consists of 5 items, each representing a different aspect of medication 
taking. We calculated a total score (all 5 items, possible range 5-25) and separate scores for 
non-intentional non-adherence (i.e. item 1: forgetting, possible range 1-5) and intentional 
non-adherence (i.e. items 2-5, possible range 4-20). Higher scores indicate higher adherence. 
The MARS has been used extensively to measure adherence in patients with chronic diseases 
and has shown good reliability (internal and test-retest) and validity (convergent and 
criterion) (Horne, 2004). Internal consistency (Cronbach’s α) for this study was .71 for the 
total score and .79 for the intentional non-adherence subscale. 
The Beliefs about Medication Questionnaire (BMQ) (Horne & Weinman, 1999) 
The two, 5-item BMQ-Specific subscales were used in the current study. These represent: a) 
beliefs about the necessity of a patient’s medication (Necessity) and b) concerns/beliefs about 
the risks and/or negative effects of taking their medication (Concerns). Higher scores equate 
to higher necessity and higher concerns. The BMQ-specific subscales have shown good 
reliability and validity amongst patients with varied illnesses including heart conditions, 
asthma and diabetes (Horne, Weinman, & Hankins, 1999). Internal consistency (Cronbach’s 
α) was .84 for BMQ-necessity and .76 for BMQ-concerns.  
The Brief Illness Perception Questionnaire (BIPQ) (Broadbent, Petrie, & Weinman, 
2004)  
The BIPQ consists of 8 separate items (consequences, timeline, personal control, treatment 
control, identity, illness concern, coherence (understanding) and emotional representation) 
relating to the patient’s illness (their stroke or TIA), each scored from 1-10, therefore internal 
reliability statistics are not appropriate. Higher scores indicate a greater belief in each 
construct (e.g. higher belief that a patient’s treatment can control their illness (treatment 
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control); a belief that their illness will last for a longer period (timeline)). The BIPQ provides 
an easy-to-complete, psychometrically robust measure of the major components of illness 
perceptions (Broadbent et al., 2004). 
Perception of benefits (Trewby et al., 2002) 
Following Trewby et al. (2002) and a previous study with stroke survivors (O’Carroll et al., 
2011), participants were asked to indicate their perception of the benefits (0-100%) provided 
by their stroke medication over the next five years (i.e. a single item).  
Mini-Mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 1975)  
The MMSE is a brief, valid and reliable instrument which has been extensively used to detect 
cognitive impairment in both research and clinical settings, including stroke research. Correct 
responses are totalled to give a maximum possible score of 30. The aim was to exclude 
participants with cognitive difficulties which could affect study participation. To this end the 
conventional cut-off score of 23 was used, as no elderly psychiatrically healthy control 
subject scored <24 in the initial study (Folstein et al., 1975). All participants in the current 
study scored 26 or higher, thus there were no exclusions using this criterion. 
Procedure 
Patients were screened for the brief intervention by completing a questionnaire around 3 
months after discharge. Inclusion criteria were: less than maximum MARS scores (i.e. <25), 
and taking at least one anti-hypertensive medication. Exclusion criteria were: receiving help 
in taking medications or using a pharmacy-supplied Dosette box (where tablets are pre-sorted 
into daily compartments). A power calculation indicated a sample size of n=30 in each 
treatment arm would detect a medium effect on MEMS adherence. 
Two brief sessions, two weeks apart were conducted by a trained Research Fellow for 
both the Intervention and Control groups, either in the participant’s home or at the Wellcome 
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Trust Clinical Research Facility at the Western General Hospital; travel expenses were 
reimbursed in the latter case.  
Intervention condition 
Session 1 (Implementation Intentions). The main focus of Session 1 was to address automatic 
aspects of medication-taking behaviour by helping each patient develop an effective 
medication-taking routine using an Implementation Intentions approach. This approach 
corresponds to items 1.4 ‘Action Planning’ and 7.1 ‘Prompts/Cues’ in the taxonomy for 
behaviour change techniques developed by Michie et al. (2013).  
Before formulating the plan, participants were asked to describe how they currently took 
their anti-hypertensive medication. This was audio-taped, and following Session 1, the 
Research Fellow coded whether the participant had mentioned a time, place, or activity (each 
as yes or no) in their description of medication-taking (e.g. ‘around 8 o’clock in the morning 
with my breakfast’ would constitute a time and activity). The number of ‘yeses’ was then 
totalled to give ‘number of freely mentioned II (Implementation Intentions) cues’ (range 0-3), 
which was used in the moderator analysis.  
Participants were then asked to formulate an Implementation Intentions plan by writing 
down exactly when and where they would take their medication, using the format of an if-
then plan i.e. ‘If it is time X in place Y and I am doing Z, then I will take my blood pressure 
pill’ by linking their medication-taking to something that they did every day (e.g. ‘If it is 8 
am and I am in the bathroom and I am about to brush my teeth, then I will take my blood 
pressure tablet’). Participants were helped to complete an individualised worksheet plan for 
each scheduled daily dose of their primary anti-hypertensive medication, and then to read this 
through until they could remember it without looking at the written plan.  
Session 2 (Modifying dysfunctional beliefs).  
The Implementation Intentions plan was reviewed at the beginning of Session 2 and any 
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required changes were made following the methods described by Sniehotta (Sniehotta, 
Scholz, & Schwarzer, 2006). Session 2’s main focus was to address reflective aspects of 
behaviour by eliciting and questioning any mistaken illness and/or medication beliefs. 
Responses on the BIPQ and BMQ were used as the basis for eliciting beliefs regarding a 
participant’s medication (e.g. beliefs regarding side-effects, interactions between medicines 
etc.) and/or regarding their stroke (e.g. underlying risk factors, long-term effects). 
Participants were not told their scores on the BMQ and BIPQ, rather these were used to 
guide questions regarding potential issues, particularly if the participant did not freely 
volunteer these at the interview (e.g. if the participant reported that they didn’t mind taking 
medication, but their score on the BMQ question ‘I sometimes worry about the long-term 
effects of my medicines...’ was ‘agree’ or ‘strongly agree’, the researcher would ask ‘Do you 
ever worry about the long-term effects of taking your medication’). The Research Fellow 
then aimed to provide evidence which would help participants come to believe that the 
necessity of their medication was more important that any concerns they had about their 
prescribed medication (Horne & Weinman, 1999). For example, if a patient expressed 
concerns about becoming physically dependent on their anti-hypertensive medication; the 
Research Fellow would provide information and give reassurance about the lack of evidence 
for any dependency effects. This approach corresponds to items 5.1 ‘Information about health 
consequences’ and 5.2 ‘Salience of consequences’ in the taxonomy for behaviour change 
techniques reported by Michie et al. (2013). 
Control condition 
Participants in the Control group also received visits from the Research Fellow at Session 1 
and 2. During these sessions, the Research Fellow talked in general, non-medication related 
terms to the participant about their stroke and its aftermath (e.g. how they and their family 
had coped) in order to control for any effects of attention or social contact.  
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Both groups 
The MEMS pill bottle was filled on a monthly basis with the patient’s own anti-hypertensive 
medication and MEMS data was recorded from the day after Session 2 for 3 months. Follow-
up was the same in both groups and data on all measures were collected at the same time 
points for both treatment arms. For each of the next two months (Sessions 3 and 4), the 
Research Fellow made a brief visit to refill the MEMS pill bottle and download an electronic 
reading from the MEMS cap onto a laptop PC. The BIPQ, BMQ and perceptions of 
medication benefits measures were also completed by the participant at the first of these 
visits. At 3-months (Session 5), the Research Fellow made a final visit to take a last MEMS 
cap reading and collect the MEMS pill bottle. The participant also completed a final version 
of the outcome measures.  
Randomisation  
Randomisation to either the Intervention or Control arm was carried out independently by the 
Edinburgh Clinical Trials Unit, using a minimisation algorithm. Participants were blinded to 
treatment allocation. 
Training of Research Fellow  
The Research Fellow is a UK registered Health Psychologist with over 10 years’ experience 
of working in applied settings. She was trained in the intervention by the Principal 
Investigator, who had been previously trained in the intervention used by Petrie (Petrie, 
Cameron, Ellis, Buick, & Weinman, 2002) in eliciting and addressing mistaken beliefs. Both 
the intervention and control group sessions (1 and 2) were piloted via role-play with the 
Principle Investigator acting as a pseudo-patient. These sessions were video-recorded, and 
feedback was given to the Research Fellow, after which minor modifications were made to 
the procedure.  
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Statistical Analysis 
An a priori decision had been made to exclude all participants with no data on the primary 
outcome measure (the MEMS pill bottle) from the analysis, in accordance with the published 
protocol (O’Carroll et al., 2010). Four people randomised to treatment were excluded from 
the analysis as they did not use the MEMS pill bottle (see Supplemental Figure S1: three 
became ineligible before starting the intervention and the other refused the use of the MEMS 
bottle at session 2); 58 patients were therefore analysed as allocated. A further 4 people were 
lost to follow-up (Supplemental Figure S1); these four are included in the analyses. Drop-
outs and/or those with missing data did not differ by treatment group (χ2(2)=0.5, p =.766), 
nor on any of the pre-treatment outcome measures, gender, Scottish Index of Multiple 
Deprivation (SIMD), MMSE scores or overall MEMS scores (data available from the 
authors).  
Missing data was addressed by using multiple imputation, via ICE (Imputation of 
Chained Equations) in the Stata software package. Five datasets were created for pooled 
analysis and test statistics were pooled using Rubin’s rules (Rubin, 1987). All other analysis 
was carried out in SPSS version 19: t-tests and χ2 were used to test basic differences between 
treatment groups; Pearson’s r was for first-order correlations, with the exception of MARS 
scores (which had ceiling effects), where Spearman’s rho was used. Repeated measures 
Analysis of Variance (ANOVA) was used to compare changes in outcome measures over 
time.  
Bootstrapping procedures (based on 5,000 samples) were used to estimate confidence 
intervals for indirect effects through the proposed mediators. This method was chosen as it  
makes no assumptions about the distribution of indirect effects and can be applied to small 
samples with a degree of confidence (Preacher & Hayes, 2004). Significant mediator 
(indirect) effects are found when confidence intervals exclude zero. Variables were 
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standardised before analysis to enable comparison of effect sizes. Moderator effects were 
examined via hierarchical regression incorporating interaction terms and simple slopes 
analyses (Aiken & West, 1991). Moderator variables were centred before analysis to reduce 
essential multi-collinearity. 
Results 
Intervention participation 
Eighty-five people were invited to take part in the intervention; 62 agreed and were 
randomised to either the Brief Intervention or the Control group; four (2 in each arm) did not 
use the MEMS pill bottle and were excluded from the analysis (Supplemental Figure S1).  
There were ceiling effects for the MARS scores with 59% of participants taking part in the 
intervention having the maximum possible sub-optimal adherence score (i.e. MARS=24) - all 
reporting that they only ‘rarely’ forgot their medication. There were no differences between 
those in the Intervention versus the Control group on any of the socio-demographic variables 
or pre-treatment measures, suggesting the randomisation procedure was effective. 
Primary outcome measure – MEMS electronic pill bottle 
Results on the main outcome measure are fully reported in the simple effects article 
(O’Carroll et al., 2013). In brief, the Intervention group had higher overall adherence than the 
Control group on all MEMS measures (percentage of total doses taken: Intervention group 
mean 99% versus Control 94%, 95% CI for difference (-1.6, 9.0); percentage of days correct 
dose taken: Intervention group mean 99% versus Control 93%, 95% C.I.(-1.8, 9.4)), but this 
was only significant for percentage of doses taken on schedule (Intervention group mean 97% 
versus Control mean 87%, 95% CI for difference (0.2, 16.2), p = .048). There were no time 
or treatment group by time interaction effects in any of the MEMS analyses.  
MARS Scores 
Figure 1 shows the changes in scores in self-reported adherence (MARS) from pre-
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intervention to follow-up. There were significant time (mean increase 0.62, 95% C.I. (0.3, 
0.9), p <.001) and interaction effects (mean difference for Intervention minus Control 0.61, 
95% C.I. for difference (0.1, 1.2), p = .027) for total MARS scores, with overall higher 
adherence at follow-up, but a significantly greater improvement in the Intervention group1.  
Both non-intentional (i.e. MARS item 1) and intentional (i.e. MARS items 2-5) adherence 
also showed significant increases over time (non-intentional mean increase pre-treatment to 
follow-up 0.26, 95% C.I. (0.1, 0.4), p < .001; intentional mean increase 0.39, 95% C.I. (0.1, 
0.4), p < .001), and greater, though not significant, increases in the Intervention versus the 
Control group (non-intentional mean difference (Intervention minus Control) 0.15, 95% C.I. 
(-0.1, 0.4), p = .138; intentional mean difference 0.27, 95% C.I. (-0.2, 0.7), p = .202). 
Beliefs about Medication and Illness  
Full details of between group differences on the BMQ, BIPQ and perceived benefit of 
medication are reported in the simple effects article (O’Carroll et al., 2013). In brief, BMQ 
necessity minus concerns significantly increased from pre-treatment to follow-up and BMQ 
concerns significantly decreased in both groups (see Supplemental Table S1). There was also 
                                                 
1 Given the skewed nature of the MARS scores, non-parametric between group tests on 
MARS total scores were also conducted at pre-treatment (Mann-Whitney U = 478.5, p = 
.975) and follow-up (U = 286.0, p = .020), as well as repeated measures on the MARS total 
scores from pre-treatment to follow-up for the Intervention group (Wilcoxon=153.0, p < 
.001) and the Control group (Wilcoxon = 63.5, p = .185) separately. These non-parametric 
tests support the findings of the repeated measures analysis above, with significantly higher 
self-reported MARS adherence in the Intervention arm at follow-up compared to the Control 
group. 
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an interaction effect with BMQ concerns having a significantly greater decrease by follow-up 
in the Intervention versus the Control group (mean difference 1.3, 95% CI (0.1-2.5), p = 
.047). There were no significant effects of changes in beliefs about illness (BIPQ) or 
perceived benefit of medication as a result of the intervention. 
Predicting adherence: Regression analyses 
In order to examine whether changes in illness and medication beliefs as a result of the 
intervention were predictors of adherence, hierarchical regression analysis of changes in 
medication and illness beliefs from pre- to post-treatment on percentage of doses taken on 
schedule measured over the 3-month follow-up period was conducted (Table 1). The final 
model is significant (F (11,44) = 3.1, p = .004) and explains 44% of the variance in 
percentage doses taken on schedule (adjusted R2 = 30%), with older age (ß = .444, p = .002), 
smaller reductions2 in BMQ concerns (ß = .335, p = .022), higher scores on the MMSE (ß = 
.302, p = .036) and being in the Intervention treatment group (ß = -.293, p = .033) being 
significant predictors of higher adherence. Pooled results following multiple imputation 
showed similar effects, with pooled significant effects for age (p = .006), MMSE (p = .034) 
and change in BMQ concerns (p = .025), although treatment group was no longer significant 
(p = .108); amount of variance explained was 35-39% (adjusted R2 = 19-25%).  
                                                 
2 This seems contrary to expectations, where greater (rather than smaller) reductions in concerns would be 
expected to relate to higher adherence. We propose that, as the Research Fellow was tasked with providing 
accurate, factual answers to patients’ concerns, participating in the intervention may have heightened thinking 
about any negative effects of a patient’s medication, resulting in a short-term increase in BMQ concerns for 
some participants. However, BMQ necessity minus concerns increased from pre- to post-treatment in the 
intervention, but not the control, group; this suggests that any increases in BMQ concerns in this group may 
have been outweighed by increases in BMQ necessity, which may have led to higher adherence at follow-up. 
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Mediators of treatment group effect 
The next step was to investigate whether the improved adherence in the Intervention group 
was mediated by changes in either beliefs and/or forgetting. A pre-requisite for a mediator 
variable is that all variables should have significant first-order correlations. The only variable 
meeting criteria for a mediator variable was change in BMQ concerns from post-treatment to 
follow-up, although change in forgetting (i.e. MARS item 1) from pre-treatment to follow-up 
was near to meeting criteria. Table 2 shows the indirect effects on percentage of doses taken 
on schedule and the regression coefficients for the a, b, c and c' paths are shown in Figure 2. 
The model was significant (F (3, 51) = 5.1, p =.004 and explained 23% of the variance in 
percentage of doses taken on schedule (R2 = .230; adjusted R2 = .184). The results of the 
bootstrap analyses indicate that there was an overall significant mediation effect of both 
variables together (95% C.I. (-0.383, -0.031)), as well as separate significant mediation 
effects of reduction in BMQ concerns from post-treatment to follow-up (95% C.I. (-0.218, -
0.007)) and reductions in forgetting from pre-treatment to follow-up (95% C.I. (-0.340, -
0.002)). The effect of treatment group on percentage of doses taken on schedule controlling 
for reduction in both BMQ concerns and MARS forgetting was not significant (95% C.I. (-
.37, .14); p = .381), indicating that a moderate part of the effect of treatment group on 
percentage of doses taken on schedule could be explained by the indirect effect of these two 
variables. The contrast term for changes in BMQ concerns versus changes in forgetting 
indicates there was no difference in the magnitude of the effect of these two variables (95% 
C.I. (-0.115, 0.249)), meaning it is not possible to speculate as to which component of the 
intervention was more effective in increasing adherence. There were no other mediator 
effects of changes in illness or medication beliefs from pre- to post-treatment or from pre-
treatment to follow-up on any measures of adherence. 
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Moderators of treatment group effect 
At the beginning of session 1 the Research Fellow asked participants from both groups if they 
already had an established routine for medication taking, and recorded the number of 
Implementation Intentions cues (i.e. activity, time or place) spontaneously mentioned when 
describing this routine. Only one patient (2%) reported having no routine, 12 (21%) 
mentioned one Implementation Intentions cue (8 time and 4 activity), 42 (72%) mentioned 
two cues and 3 (5%) mentioned all three. The number of Implementation Intentions cues 
mentioned at first interview was significantly positively correlated with all MEMS adherence 
measures at follow-up (e.g., percentage of doses taken on schedule (r = .44, p = .001)).  A 
hierarchical liner regression analysis including treatment group at Step 1, number of pre-
treatment Implementation Intentions cues at Step 2, and the interaction of treatment group 
and number of Implementation Intentions cues at Step 3 was significant (F(3,5) = 7.1, p 
<.001) and explained 28.4% of the variance (adjusted R2 = 24.4%) in percentage of doses 
taken on schedule, with both number of Implementation Intentions cues (ß = -.37, p = .003) 
and the interaction (ß = .27, p = .025) being significant (but not treatment group; ß = .15, p = 
.213). This indicates that the number of initial Implementation Intentions cues reported by 
participants moderated the effect of treatment group on follow-up adherence. Simple slopes 
(Aiken & West, 1991) were computed for the effect of treatment group on adherence at two 
levels of initial Implementation Intentions cues: low i.e. <=1 and high i.e. >=2 (Figure 3). 
Figure 3 shows that for low levels of initial Implementation Intentions cues, forming 
Implementation Intentions plans (i.e. being in the Intervention group) resulted in significantly 
higher adherence at follow-up compared to the Control group (ß = -1.2, p = .016), whereas 
there was no effect of treatment group for those with high initial levels of Implementation 
Intentions cues (ß = -0.2, p = .435). Cohen’s f2 was used to estimate effect size: this estimates 
the ratio of systematic variance accounted for by the moderator relative to unexplained 
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variance in the criterion (Aiken & West, 1991). For this analysis, f2 = .10 indicating a small to 
medium effect of moderation (as defined by Cohen (1988): i.e. .02 is a small effect, and .15 is 
a medium effect). 
Discussion 
This pilot intervention is the first to show that adopting a simple If-then plan, coupled with 
eliciting and modifying patients’ medication concerns, can significantly improve adherence 
to medication in stroke survivors. In contrast to some other studies with stroke survivors (e.g. 
Bushnell et al., 2010), overall adherence appeared to be relatively high. Reasons for this may 
include the fact this was an older, higher socio-economic sample (both of which are 
associated with higher adherence (O’Carroll et al., 2011)) or that many patients already had 
effective medication-taking routines (as evidenced by the high number of Implementation 
Intentions cues already used), which may be linked to the fact that many were on established 
multiple medications for chronic conditions. However, it is equally plausible that the high 
adherence represents a strong Hawthorne effect attributable to the use of the MEMS pill 
bottles over a three-month period. It seems likely that the use of MEMS pill bottles led to a 
significant increase in adherence in both treatment and control groups.  
Despite the high adherence overall, the brief intervention improved the regularity of pill-
taking by 10% over and above any non-specific effects of MEMS pill bottles and additional 
therapeutic contact.  Although the corresponding 5% increase in overall pills taken was not 
significant, instructions for taking common anti-hypertensives often advise taking medication 
at the same time each day, precisely to reduce forgetting (e.g. Lisinopril: ‘Try to take your 
dose at the same time each day to avoid missing any doses’). Many of the patients in this 
study were also taking common cholesterol-lowering medications, where a delay in taking a 
dose should lead to a missed dose as indicated by the instructions (e.g. Simvastatin: ‘If you 
miss a dose, just carry on with the next one as normal. Do not take an extra one to make up’). 
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Therefore regularity of pill-taking may be just as important as numbers of doses taken in 
ensuring good clinical outcomes. Is a 10% increase in adherence clinically significant?  
Bailey, Wan, Tang, Ghani, and Cushman (2010) reported that increasing adherence to blood-
pressure medication by just one tablet per week could reduce the hazard of stroke by 8-9% 
and of death by 7%. 
Overall, there was greater improvement in beliefs about medication (i.e. reduction in 
concerns) in the Intervention group, and evidence for a mediation effect of reduction in 
concerns about medication (from post-treatment to follow-up) and forgetting medication 
(from pre-treatment to follow-up) on objectively-measured adherence. Thus the dual goals of 
increasing adherence by improvements in both non-intentional non-adherence, through the 
process of reducing forgetting, and intentional adherence, via the process of reducing 
concerns about medication, was partly achieved. This intervention was tailored to each 
participant, and it has been suggested that simply tailoring to current behaviour and personal 
characteristics may have considerable effects on behaviour change (Noar, Benac, & Harris, 
2007). Participants in the present study were not given on feedback on their initial or 
subsequent BMQ scores; rather these were used to guide the interviewer’s questions to help 
elicit specific concerns which could then be personally addressed. Participants frequently 
commented that it was beneficial to be able to get answers to their personal queries, in 
preference to the usual mass-produced media (such as Patient Information Leaflets). This, 
coupled with the changes in BMQ concern scores from pre-treatment to follow-up, suggests 
that changes in beliefs did contribute to increased adherence. 
Consistent with previous research in stroke survivors (O’Carroll et al., 2011), illness 
perceptions were not related to adherence in the present study. The majority of this 
sample reported that they had no on-going symptoms from their stroke and thus viewed their 
illness as time-limited and/or ‘over’, and therefore as having no great impact on their lives or 
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medication-taking. It is also possible that there was a bias in those taking part in the 
intervention towards having fewer lasting symptoms as a result of their stroke. However, it 
was not possible to explore this further from the current data. 
Previous research aimed at increasing medication adherence has often had limited success 
(Haynes, Ackloo, Sahota, McDonald, & Yao, 2008); the present study adds to current 
evidence by demonstrating that a brief intervention using a combined approach to 
simultaneously address both reflective and automatic aspects of behaviour can increase 
medication adherence in a population of elderly stroke survivors. These findings support 
temporal self-regulation theory in that implementation intentions formation may be viewed as 
a self-regulatory tool, which can help individuals with cognitive impairment attain their goals 
via developing automatic processes, whilst the aim of addressing any dysfunctional beliefs 
was to alter patients’ views of the cost-benefit equation in favour of taking their medication 
on a regular basis. 
Many of the patients had been on blood pressure medicine and/or other long-term 
medication before their stroke or TIA, and many had already established regular medication-
taking routines. The number of Implementation Intentions cues spontaneously mentioned at 
the first interview was strongly related to MEMS adherence at follow-up, and also moderated 
the effect of treatment group, such that the effect of the intervention was mainly apparent in 
patients with a poorly-defined initial routine (i.e. had weak positive habits). This could be 
because they benefited from help in setting up a routine, or because those with a well-
established routine may have been less amenable to change it, even when it was not always 
working successfully. Lally and Gardner (2011) reasoned that deliberate intentions to 
perform a behaviour have a reduced influence when habits are already strongly established. 
The current findings lend further support to temporal self-regulation theory, where past 
behaviour is viewed as an important determinant of future behaviour. They also indicate that 
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Implementation Intentions planning is likely to be most effective at increasing adherence in 
patients who are new to medication-taking, or have failed to establish a regular routine by 
their own devices, suggesting that early intervention may be key. 
Strengths and Limitations 
A critical evaluation of adherence interventions (Horne, Weinman, Barber, Elliot, & Morgan, 
2006) identified six consistent weaknesses in the field: 1) narrow focus for intervention, in 
particular a failure to consider both intentional and non-intentional non-adherence, 2) “one 
size fits all” approach i.e. not patient-centred, 3) failure to specify the content of the 
intervention, 4) “black box” evaluation, 5) lack of theoretical framework and 6) little or no 
process evaluation.  Our study has addressed all of these issues. 
The main limitation of this pilot study was that the Research Fellow was not blinded to 
treatment arm of the patients, as she both delivered the intervention and carried out the 
analysis. However, this should not have had any major effect on the current findings as the 
primary outcome measure was objectively-recorded electronic MEMS readings, and the 
remaining outcome measures were posted out to and completed by participants in advance of 
the Research Fellow visits. Baseline data was not recorded for the MEMS; however there 
were no difference in pre-treatment self-reported adherence between groups, and self-
reported adherence also showed greater increases in the Intervention versus the Control 
group, suggesting the differences found in MEMS readings would not have been present at 
pre-treatment. Nonetheless, it would have been preferable to have a run-in period with the 
MEMS pill bottle to establish baseline adherence on the objective measure; however, this 
was not feasible within the scope of this pilot study.  
The high levels of adherence observed in both groups in the current study, plus the fact 
that those reporting they already used two or more Implementation Intentions cues had higher 
adherence at follow-up in both treatment arms, suggests that the intervention may have had 
23 
 
greater impact had the intervention been targeted at participants with lower initial levels of 
adherence. Additional limitations include the small sample size and the fact that there was 
only one item measuring non-intentional non-adherence. Although this pilot was conducted 
in stroke survivors, it is plausible that it may be generalizable to other patients on preventive 
medication for chronic conditions. 
Conclusions 
To our knowledge, no other published study has used an intervention aimed at increasing 
adherence in a group of stroke survivors via helping them devise medication-taking routines 
in conjunction with aiming to elicit and address any mistaken medication and/or illness 
beliefs. These findings demonstrate that a simple, individually tailored, theory-based 
intervention resulted in a significant increase in objectively measured adherence over a 3-
month period. In addition, it would appear that the combined approach of addressing both 
automatic and reflective behaviour was instrumental in the outcome, as the treatment effect 
was mediated via a reduction in both forgetting and concerns about medications, and 
moderated by the degree of pre-existing medication-taking routines. 
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Table 1. Multiple hierarchical linear regression predicting percentage of doses taken on schedule (full data: n =57) 
  ß 
Step 1 
ß 
Step 2 
ß 
Step 3 
ß 
Step 4 
ß 
Step 5 
Change 
R2 for 
step 
Total R2 Adjusted 
R2 
1 Demographics      .188** .188** .151 
 Age .310* .402** .396* .381** .444** 
   
 Gender -.115 -.152 -.155 -.277 -.236 
   
 SIMD  -.236 -.188 -.184 -.256 -.196 
   
2 Stroke severity      .051 .239* .163 
 MMSE Total Score  .211 .205 .348* .302* 
   
 Severity  .113 .107 .105 .071 
   
3 Illness perceptions      .002 .240* .130 
 BIPQ Treatment Control pre-post   .027 .083 .007 
   
 BIPQ Timeline pre-post   .041 -.009 -.080 
   
4 Medication beliefs      .135* .375* .236 
 BMQ Specific Necessity pre-post    .181 .105 
   
 BMQ Specific Concerns pre-post    .386* .335* 
   
 Perception of Medication Benefits    .080 .146 
   
5 Treatment Group      .062* .437 .297 
 
Treatment group 
    
-.293* 
   
SIMD: Scottish Index of Multiple Deprivation; MMSE: Mini Mental State Exam; BIPQ: Brief Illness Perception Questionnaire;  
BMQ: Beliefs about Medication Questionnaire. *p <.05. **p <.01. 
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Table 2. Mediation of the effect of treatment on percentage of doses taken on schedule through reduction in forgetting and BMQ 
concerns from post-treatment to follow-up 
 Point estimate Product of coefficients Bca 95% C.I. 
  SE Z Lower Upper 
BMQ concerns from post-treatment to follow-up -.067 .048 -1.43 -.218 -.007 
Forgetting (MARS item 1) -.082 .070 -1.17 -.340 -.002 
Total -.151 .085 -1.77 -.383 -.031 
Contrast (BMQ versus forgetting) .013 .085 0.16 -.115 .249 
 
BMQ=Beliefs about Medication Questionnaire; Bca= bias corrected and accelerated bootstrapping confidence intervals; 
intervals are significant if they do not contain zero (Preacher & Hayes, 2004).  
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Figure 1. Total scores on the Medication Adherence Report Scale (MARS) from 
pre-treatment to 3-month follow-up (Error bars represent 95% C.I. for mean) 
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Figure 2. Effects of treatment group on percentage of doses taken on schedule by 
changes in medication beliefs and forgetting 
  
b
1
) BMQ 
concerns from 
post to follow -up 
a) Treatment 
group 
c) % doses 
taken on 
schedule 
.27* 
c= -.26
#
; c’= .11 
-.25
#
 
b
2
) Reduction in 
forgetting 
.23 
.33** 
 
#
 p<.06, *p<.05, **p<.01; BMQ=Beliefs about Medication Questionnaire
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Figure 3. Simple slopes analysis for the moderator effect of number of initial 
Implementation Intentions (II) cues on the relationship between treatment group 
and percentage of doses taken on schedule 
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Supplemental Figure S1. CONSORT diagram 
Completed consent forms and 
assessed for eligibility for Part 1
(n=494) 33 declined to take part
2 incomplete forms 
52 were not eligible for Part 1: 
50 had had a previous stroke/TIA
2 had not had a stroke/TIA
Eligible for Part 1 and sent 
baseline assessment 
questionnaires (n=407) 19 declined to complete questionnaires
24 failed to return questionnaires 
6 replied that hadn’t had stroke/TIA
3 ineligible for Part 2 (at phone call)
Randomised (n=62)
Invited to take part in Part 2  
intervention (n=85) Not randomised:
21 declined to take part in Intervention
2 failed to respond to invitation
Lost to follow-up (n=2): 
2 hospitalised (non-stroke)
Lost to follow-up (n=2)
1 hospitalised (non-stroke); 1 relocated 
Analysed (n=29)
Excluded from analysis (n=2):
1 did not receive intervention (ineligible), 
1 declined to use MEMS
Analysed (n=29)
Excluded from analysis (n=2):
2 did not receive intervention (ineligible)
Allocated to control group(n=31)Allocated to brief intervention (n=31)
Part 1 assessment measures 
returned and assessed for 
eligibility for Part 2 (n=355) 270 excluded from Part 2 (main reason):190 MARS=25
54 not on anti-hypertensives
10 had help taking medication 
3 reported using Dosette box
13 other (7 missing data, 2 own box, 4 too late) 
Part 1: 
Assessment 
for Intervention
Part 2: 
Intervention
1st assessment (n=31)
Received allocated intervention (n=30)
Did not receive intervention (n=1): 
now ineligible: using Dosette box
1st assessment (n=31)
Received allocated intervention (n=29)
Did not receive intervention (n=2):
now ineligible: not taking anti-hypertensive
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Supplemental Table S1. Mean scores (s.d.) and results of ANOVAs for Beliefs about Medication by time and treatment group (n=58) 
  
Pre Post Follow-up 
Group x time Group Time 
Pooled F(2,x) Pooled F(1,x) Pooled F(1,x) 
BMQ Specific Necessity Intervention 17.4 (3.0) 18.1 (2.6) 18.5 (2.5) 
0.8, p=.460 0.1, p=.743 2.7, p=.066 
Control  18.2 (3.0) 17.9 (3.0) 18.5 (2.7) 
BMQ Specific Concerns Intervention 13.2 (3.2) 11.9 (3.7) 11.0 (2.5) 
3.1, p=.047 .01, p=.924 9.2, p<.001 
Control  12.9 (3.4) 11.7 (3.7) 11.9 (3.0) 
BMQ Necessity minus Concerns Intervention 4.2 (4.5) 6.1 (4.9) 7.4 (3.4) 
2.5, p=.081 0.02, p=.879 10.8, p<.001 
Control  5.3 (4.6) 6.2 (4.9) 6.6 (4.3) 
Note: df for F (i.e. x) are adjusted by inter-imputation variance to give pooled p-values and so vary by each statistic;  
BMQ: Beliefs about Medication Questionnaire 
 
 
 
 
